\
&
Contact us
\
&
Contact us
Published on | 1 month ago
Programmes HorizonEU L+FThe Certificate of Financial Statement (CFS) template has been adapted on 1 March 2025, with specific changes to the checklist, as explained on the last page of this document. General information about CFS is explained in our infosheet.
The European Liaison Office of the German Research Organisations based in Brussels (KOWI) has gathered in November 2024 internal auditors of German universities and research institutions, the ones responsible for a.o. the issuing of the CFS. Together with two auditors from the European Court of Auditors and the ERC Executive Agency, they discussed the challenges they see for the first audits in Horizon Europe, in general and specific points of the CFS (former template). The report of this discussion can be found here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space AI Continent Deployment: Best use of technologies
The Openverse project hosted last week a high-impact workshop, “National Initiatives and the European Partnership on Virtual Worlds,” aligning stakeholders around the European Commission’s Virtual Worlds strategy. The initiative, rooted in the July 2023 Communication on Web 4.0 and Virtual Worlds, aims to build sustainable, inclus... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
